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Abstract
Background: The introduction of highly active antiretroviral therapy (HAART) has dramatically changed the prognosis 
of human immunodeficiency virus (HIV) infection, with a significant decline in morbidity and mortality.
Changes in body fat distribution are a common finding in individuals with HIV infection being treated with
antiretrovirals, and this condition (collectively termed lipodystrophy syndrome) is associated with depletion of
subcutaneous fat, increased triglycerides and insulin resistance. Obesity, particularly visceral obesity, is associated with
increased risk of cardiovascular disease. Therefore, estimating visceral fat distribution is important in identifying
subjects at high risk for cardiovascular disease.
The aim of our study was to evaluate whether perirenal fat thickness (PRFT), a parameter of central obesity, is related to
ophthalmic artery resistance index (OARI), an index of occlusive carotid artery disease in HIV-1 infected patients.
Methods: We enrolled 88 consecutive HIV-1-infected patients receiving highly active antiretroviral therapy for more 
than 12 months, in a prospective cohort study. Echographically measured PRFT and OARI, as well as serum metabolic 
parameters, were evaluated. PRFT and OARI were measured by 3.75 MHz convex and 7.5 MHz linear probe, respectively.
Results: The means of PRFT and OARI in HIV-1-infected patients with visceral obesity was considerably higher than in 
patients without it (p < 0.0001 and p < 0.001, respectively). Using the average OARI as the dependent variable, total 
serum cholesterol level, HDL, triglycerides, glycemia, sex, blood pressure, age and PRFT were independent factors 
associated with OARI. A PRFT of 6.1 mm was the most discriminatory value for predicting an OARI > 0.74 (sensitivity 
78.9%, specificity 82.8%).
Conclusions: Our data indicate that ultrasound assessment of PRFT may have potential as a marker of increased 
endothelial damage with specific involvement of the ocular vascular region in HIV-1-infected patients.
Background
The introduction of highly active antiretroviral therapy
(HAART) has dramatically changed the prognosis of
human immunodeficiency virus (HIV) infection, with a
significant decline in morbidity and mortality [1]. Treat-
ment with antiretroviral agents has uncovered a syn-
drome of abnormal fat redistribution, impaired glucose
metabolism, insulin resistance and dyslipidemia, collec-
tively termed lipodystrophy syndrome [2-4] potentially
contributing to cardiovascular risk [5,6]. Measurement of
the inferior part of the perirenal fat has been shown to be
an easy and reliable imaging indicator of visceral obesity
and cardiovascular risk factors [7]. Increased cardiovas-
cular risk has been shown to be related to carotid intima
medial thickness as well as to subclinical atherosclerotic
vessel damage [8-10]. Moreover, a direct correlation
between intima-media thickness (IMT) of common
carotid and ophthalmic artery resistance index (OARI)
has been observed in HIV-1 patients [11]. Our hypothesis
was that ultrasound OARI measurement may be a poten-
tial marker of increased endothelial damage as an early
predictor of IMT increase.
It is important to determine which group of HIV-1
patients is at increased risk for atherosclerosis. Identifica-
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tion of predictive factors for the development of cardio-
vascular complications would be very useful, because
preventive intervention could then be undertaken for
HIV-1 patients.
Visceral obesity, more than overall obesity, plays a key
role in the development of cardiovascular disease [12].
Thus, estimating visceral fat distribution is important in
order to identify subjects with a high risk for cardiovascu-
lar disease.
Visceral obesity can be evaluated using several tech-
niques, including ultrasound, CT (gold standard) and
MRI. Measurement of visceral fat volume using ultra-
sound can as effective as using CT. The advantages of this
method are its low cost, lack of side effects, and technical
suitability [13].
It is known that there is good correlation between
intra-abdominal fat distribution and ultrasonographic
measurement of fat thickness and between perirenal fat
thickness (PRFT) and central obesity [14-18].
We performed a prospective cohort study to identify
the role of visceral fat distribution in endothelial damage
and risk. The objective of our study was to evaluate
whether ultrasound parameters of visceral obesity could
be associated with ophthalmic blood flow, playing a role
as a possible surrogate marker of cardiovascular risk in
HIV-1-infected patients.
Methods
This study was approved by the local institutional Ethics
Committee and all patients approached for the study gave
written consent to participate.
Study population
HIV-1-infected patients of Santa Caterina Novella Hospi-
tal (Galatina, Italy) were considered for this study. All
patients had documented HIV-1 infection, had been
receiving HAART for 12 months, and were older than 18
years of age. An in-depth assessment was performed,
including HIV disease history, other co-morbid condi-
tions, medication exposure and measurement of systolic
blood pressure (determined using a sphygmomanometer
with the subjects at rest in a sitting position). Smokers
were defined as individuals smoking more than 5 ciga-
rettes/day at least during the past year (in our cohort all
the patients who smoked declared they smoked > 5 ciga-
rettes/day). Subjects were excluded from participating if
they had any of the following clinical conditions: active
AIDS-defining illness, diabetes mellitus or current use of
oral hypoglycemic agents, family history of myocardial
infarction (prior to age 55 for first-degree male relatives
and prior to age 65 for first-degree female relatives), a his-
tory of coronary heart disease or stroke, uncontrolled
hypertension, active drug abuse, alcohol abuse (defined as
alcohol consumption > 30 gr/day), untreated hypothy-
roidism. Patients requiring systemic chemotherapy, radi-
ation therapy or systemic steroids were excluded. Two
groups of patients were consecutively selected. The first
group comprised HIV-1-infected patients with a diagno-
sis of visceral obesity. The second group included HIV-1-
infected patients for whom the diagnosis of visceral obe-
sity had been excluded. Diagnoses of visceral obesity were
based on ultrasound measured PRFD/BMI ratio > 0.22.
Grima et al. [16] observed that this value could be consid-
ered a potential parameter for assessing visceral fat accu-
mulation in HIV-1 infected patients.
General metabolic assessment
CD4+ cell counts, HIV ribonucleic acid (RNA) load, total
serum cholesterol level, high-density lipoprotein (HDL)
cholesterol level, glycemia, and triglyceride levels were
evaluated at baseline after a 12-h overnight fast.
For ultrasound measurement of visceral fat and oph-
thalmic artery resistance index a Logiq 5 ultrasound
scanner (General Electric Medical Systems, Wallingford,
Connecticut, USA) equipped with a 3.75 MHz convex
and 7.5 MHz linear probe was used. Sonographic evalua-
tion of visceral obesity was always performed by a single
trained sonographer blinded to the patients' data. The
visceral fat thickness was determined with a 3.75-MHz
convex transducer at a specific referee point as PRFT
(longitudinal scan along the right mid-clavicular line,
from the border of the right liver lobe to the border of the
inferior pole of the right kidney, Fig. 1) with the patient in
the supine position. OARI was measured with the patient
lying supine with eyes closed, using an ultrasound fre-
quency of 7.5 mHz and by averaging the readings from at
least three consecutive waveforms. The average of the
values was defined as the OARI (Ophthalmic Artery
Resistance Index). The transducer was applied to the
closed upper eyelid using a thick layer of acoustic gel,
minimizing the pressure on the globe (Fig. 2). The repro-
ducibility of PRFT and OARI measurement was evalu-
ated by triple determinations in 15 subjects other than
the enrolled patients. A clinically significant increase in
OARI was defined as a value > 0.75 according to previous
observations [19].
Statistical analysis
Continuous variables were reported as the mean ± stan-
dard deviation (SD) and categorical factors were reported
as percentages. Demographic characteristics and meta-
bolic variables were compared between the patient
groups by analysis of variance (ANOVA) of successive
measurements. Multiple regression analysis was used to
assess the independent association between the OARI
and PRFT adjusting for various risk factors. Total serumGrima et al. Cardiovascular Ultrasound 2010, 8:24
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cholesterol level, HDL, triglycerides, glycemia, age, sex
and blood pressure were considered as independent vari-
ables in the multivariate model.
The most discriminant cutoffs were calculated by
receiver operating characteristic (ROC) curves. Statistical
calculations were performed with MedCalc software, ver-
sion 9.6.0.0. A p-value < 0.05 was considered to be statis-
tically significant.
Results
Study population. Eighty-eight patients were recruited
during 2009. A total of 38 patients (25 men and 13
women) were in the visceral obesity group and 50 (33
men and 17 women) were in the control group. All sub-
jects were of the Caucasian race. Table 1 shows patients'
demographic and clinical characteristics. There were no
differences between the two groups with regard to age,
gender ratio, smoking status, risk factors, metabolic
parameters, BMI, CD4 cell count, viral load and HAART
duration. Plasma triglyceride levels were higher (although
without statistical significance) in patients with visceral
obesity. All HIV-1-infected patients had a backbone of
Tenofovir/Emtricitabine. Protease inhibitors (PI) had
been prescribed in 47 (53.4%) patients (27 with visceral
obesity and 20 without obesity), without statistically sig-
nificant difference between the two groups. All patients
exposed to PIs received a ritonavir-boosted PI. Non-
nucleoside reverse-transcriptase inhibitor (NNRTI) had
been prescribed in 41 (46.5%) patients (23 with visceral
obesity and 18 without obesity). The sonographic assess-
ment of PRFT and OARI provided good reproducibility,
and the intraoperator coefficient of variation was 6.2%
and 8.6%, respectively.
A t  base li ne  t he  m ea n of  PRFT a nd O ARI in HIV -1-
infected patients with visceral obesity were considerably
higher (8.1 ± 2.3 vs 3.2 ± 0.9 mm, p < 0.0001 and 0.73 ±
Figure 1 Assessment of perirenal fat diameter. Longitudinal scan (3.75 mHz) along the right midclavicular line, from the border of the right liver 
lobe to the border of the inferior pole of the right kidney. Arrows, limits of perirenal fat thickness.Grima et al. Cardiovascular Ultrasound 2010, 8:24
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0.04 vs 0.69 ± 0.03, p < 0.001, respectively) than in
patients without (Table 2). An OARI anomalous value
(0.90 mm) in HIV 1+ patients (Group B) doesn't influence
the mean values and the statistical analysis. For all 88
HIV-1-infected patients, US-measured PRFT correlated
well with OARI (r, +0.52, p < 0.001) (Fig. 3). Receiver
operating characteristic curves (ROC) indicated that the
most discriminant PRFT value for predicting an OARI >
0.74 was 6.1 mm (sensitivity 78.9%, specificity 82.8%,
AUC 0.84, p < 0.001) (Fig. 4). Using the average OARI as
the dependent variable, total serum cholesterol (Odds
Ratio 0.9, 95% CI 0.98 to 1.01), LDL (Odds Ratio 0.9, 95%
CI 0.98 to 1.04) triglycerides (Odds Ratio 0.9, 95% CI 0.98
to 1.0), glycemia (Odds Ratio 0.9, 097 to 1.1), sex (Odds
Ratio 1.0, 95% CI 0.96 to 1.05), blood pressure (Odds
Ratio 0.8, 95% CI 0.98 to 1.07), age (Odds Ratio 1.13, 95%
CI 1.04 to 1.23) and PRFT (Odds Ratio 1.44, 95% CI 1.12
to 1.85) were independent factors associated with OARI.
No statistically significant correlations between PRFT
and body mass index were found.
Discussion
Several reports have shown that HIV-1 patients have an
increased risk of cardiovascular disease [19,20]. In addi-
tion, many epidemiological studies have shown increased
visceral fat accumulation to be an independent risk factor
for cardiovascular diseases such as coronary artery dis-
ease, stroke and hypertension [21-23].
Visceral obesity can be evaluated by different tech-
niques, including CT [24-26], MRI [27-29] and ultra-
sonography [16,30-34]. However computed tomography
(CT) and magnetic resonance (MRI) are expensive and
the first method employs ionizing radiation, so they are
not suitable for large-scale use. Sonography is simple,
rapid, available, safe and is low-cost compared to CT and
MRI.
Figure 2 Assessment of ophthalmic artery resistance index with patient lying supine with eyes closed and using an ultrasound frequency 
of 7.5 mHz. The transducer is applied to the closed upper eyelid using a thick layer of acoustic gel, minimizing pressure on the globe.Grima et al. Cardiovascular Ultrasound 2010, 8:24
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In this study, the measurements were performed by a
single operator, so it was not possible to assess the inter-
operator variability.
The measurements made by two expert sonographers
do not show significant differences [13], and another
study confirms that a junior sonographer can be just as
successful as a senior sonographer [7].
Kawasaki et al. [18] measured para- and perirenal ultra-
sound thickness and reported that it significantly corre-
lated with fat thickness assessed by CT, according to
previously published data [32]. Moreover, it was shown
that scanning was simple and satisfactory images were
obtained without interference of bowel gas.
For all these reasons, we used ultrasonographic meth-
ods to assess visceral fat distribution measuring the dis-
tance between the liver and the renal hilum of the right
kidney.
PRFT is marker easily obtained during a routine ultra-
sound examination of the upper abdomen.
This examination provides information on kidney and
liver injuries as a result of HAART, on the infection itself
or on comorbidity with other viruses (HBV, HCV).
Furthermore, ultrasound assessment is an essential
method for the study of clinical staging and monitoring of
HIV patients.
The ophthalmic artery is the first major branch of the
internal carotid artery, and changes in blood flow have
provided new insights into various vascular disorders
including carotid artery stenosis and metabolic disorders.
OARI offers particular advantages due to the absence of
ultrasound obstacles and the vertical angle, which differs
from the parallel-signaling of the carotid artery [35].
Orbital circulation changes with varying degrees of
carotid stenosis [36] were observed, with a significant
relation between orbital velocity changes and carotid
occlusive disease [37]. Studies on carotid artery stenosis
have shown decreased blood flow velocity in the ophthal-
mic artery when the stenosis was greater than 70% [38],
showing that measurement of orbital vessel velocity may
be essential for evaluating the distal consequences of
carotid artery stenosis [39].
Because carotid stenosis is an independent prediction
of stroke and myocardial infarction in the general popula-
tion [40-43], our data suggest that the rate of vascular
Table 1: Demographic and clinical characteristics of HIV-1 patients receiving HAART
Characteristic A (n = 88) B (n = 38) C (n = 50) p-value
Age (years) 42 ± 8.6 41.4 ± 7.0 44.2 ± 8.2 NS
Sex (M/F) 42/26 33/17 25/13 NS
BMI (kg/m2) 23.51 ± 2.9 24.4 ± 1.8 23.4 ± 2.2 NS
PRFT/BMI 0.2 ± 0.09 0.32 ± 0.01 0.13 ± 0.04 < 0.0001
Current smoker (%) 36.3 35.2 33.3 NS
Systolic pressure 123 ± 6.8 126.9 ± 7.3 122.0 ± 6.7 NS
HIV exposure
Homosexual 42 (47.7%) 23 (46%) 19 (50%) NS
Heterosexual 31 (35.2%) 17 (34%) 14 (36.8) NS
IDU 15 (17%) 8 (16%) 7 (18.4%) NS
HCV coinfection (%) 20.5 20 20.8 NS
CD4 (cells/μl) 534.3 ± 251.6 533.8 ± 271.2 535 ± 212 NS
HIVRNA load (mean log10 copies) 2.06 ± 1.2 2.1 ± 1.01 1.9 ± 1.4 NS
Duration of HAART (months) 75 ± 40.9 82.4 ± 35.9 70.4 ± 43.6 NS
Total cholesterol (mg/dl) 184.5 ± 44.7 190.3 ± 54.9 180.9 ± 37 NS
HDL cholesterol (mg/dl) 51.5 ± 15 52.6 ± 16.2 50.8 ± 14.4 NS
Triglycerides (mg/dl) 156.1 ± 94.7 177.3 ± 97.8 142.7 ± 91.3 NS
Glycemia (mg/dl) 94.3 ± 11.8 92.8 ± 6.9 86.7 ± 9.2 NS
2 NRTI + 1 NNRTI 41 (46.5%) 23 (46%) 18 (47.3%) NS
2 NRTI + 1 PI 47 (53.4%) 27 (54%) 20 (52.6%) NS
A, all HIV+ patients; B, HIV+ patients with visceral obesity; C, HIV+ patients without visceral obesity; BMI, body mass index; PRFT, perirenal fat 
thickness; IDU, intravenous drug users; HAART, highly active antiretroviral therapy; HDL, high density lipoprotein; NRTI, nucleoside reverse 
transcriptase; NNRTI, non-nucleoside reverse transcriptase; PI, protease inhibitor; NS, not significant. All data are expressed as mean ± 
standard deviation. A p-value of < 0.05 was considered to be statistically significant.Grima et al. Cardiovascular Ultrasound 2010, 8:24
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events is likely to increase substantially in HIV patients
receiving highly active antiretroviral therapy, who have
been diagnosed with visceral obesity.
To our knowledge, this is the first study to compare vis-
ceral fat assessment and ophthalmic blood flow, in order
to find a reproducible tool for early diagnosis of endothe-
lial damage.
In conclusion, our data show that ultrasonographic
measurement of PRFT could be considered a simple and
objective parameter for early diagnosis of atherosclerosis.
Furthermore, it allows identification of patients at
increased risk of cardiovascular disease for which other
clinical studies are useful.
Clinical implications
From recent data, it appears that central fat distribution
may be of more importance in endothelial damage than
overweight alone, confirming previous studies showing
that visceral fat accumulation itself played a role as a risk
factor for atherosclerosis [44,45]. Ultrasound may repre-
sent an important step towards selecting patients at high
risk for developing metabolic syndrome, allowing early
intervention, and thus minimizing the impact of compli-
cations resulting from this condition [46].
Measurement of visceral obesity with ultrasound has
the advantage of being non-invasive, easily accessible,
economical and does not involve exposure to ionizing
radiation. Limits to the use of VAT measurement are
operator pressure, presence of bloating and poor accu-
racy for obese patients.
The determination of visceral fat by PRFT may be a
more accurate method since perirenal fat contains only
visceral adipose tissue while the single waist circumfer-
ence or waist and hip ratio circumferences (WHR) can-
not distinguish subcutaneous fat from intra-abdominal
fat [7].
Furthermore, in HIV patients it has been observed that
the determined value of ultrasound PRFT is particularly
useful for diagnosing lipodystrophy. The available data
indeed show that the thickness of the perirenal fat occurs
earlier than accumulation of fat in other body areas [15].
Figure 3 Linear regression curve of relation between echographically measured PRFT and OARI in 88 HIV-1-infected patients. Dotted line, 
95% confidence interval; PRFT, perirenal fat thickness; OARI, ophthalmic artery resistance indexGrima et al. Cardiovascular Ultrasound 2010, 8:24
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Figure 4 Receiver operating characteristics curves of Perirenal Fat Thickness (PRFT) considering Ophthalmic Artery Resistance Index 
(OARI) > 0.74 as status variable. The area under the curve was 0.84 (95% CI, 0.74 to 0.91; p < 0.001). CI, confidence interval
Table 2: Ultrasonographic PRFT and OARI measurement values in HIV-1 patients receiving HAART
Characteristic A (n = 88) B (n = 38) C (n = 50) p-value
PRFT 5.1 ± 3 8.1 ± 2.3 3.2 ± 0.9 < 0.0001*
OARI 0.70 ± 0.04 0.73 ± 0.04 0.69 ± 0.03 < 0.001**
A, all HIV+ patients; B, HIV+ patients with visceral obesity; C, HIV+ patients without visceral obesity; PRFT, perirenal fat thickness; OARI, 
ophthalmic artery resistance index. All data are expressed as mean ± standard deviation. * B vs C; ** B vs C. A p-value of < 0.05 was considered 
to be statistically significant.Grima et al. Cardiovascular Ultrasound 2010, 8:24
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